These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19207601)

  • 1. Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.
    Kakuda TN; Schöller-Gyüre M; De Smedt G; Beets G; Aharchi F; Peeters MP; Vandermeulen K; Woodfall BJ; Hoetelmans RM
    HIV Med; 2009 Mar; 10(3):173-81. PubMed ID: 19207601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
    DeJesus E; Lalezari JP; Osiyemi OO; Ruane PJ; Ryan R; Kakuda TN; Witek J
    Antivir Ther; 2010; 15(5):711-20. PubMed ID: 20710052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
    Luber AD; Condoluci DV; Slowinski PD; Andrews M; Olson K; Peloquin CA; Pappa KA; Pakes GE;
    HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers.
    Hoetelmans RM; Mariën K; De Pauw M; Hill A; Peeters M; Sekar V; De Doncker P; Woodfall B; Lefebvre E
    Br J Clin Pharmacol; 2007 Nov; 64(5):655-61. PubMed ID: 17610528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
    Kakuda TN; DeMasi R; van Delft Y; Mohammed P
    HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.
    Kakuda TN; Wade JR; Snoeck E; Vis P; Schöller-Gyüre M; Peeters MP; Corbett C; Nijs S; Vingerhoets J; Leopold L; De Smedt G; Woodfall BJ; Hoetelmans RM
    Clin Pharmacol Ther; 2010 Nov; 88(5):695-703. PubMed ID: 20881958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers.
    Blum MR; Chittick GE; Begley JA; Zong J
    J Clin Pharmacol; 2007 Jun; 47(6):751-9. PubMed ID: 17519400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.
    Huang F; Scholl P; Huang DB; MacGregor TR; Taub ME; Vinisko R; Castles MA; Robinson P
    Basic Clin Pharmacol Toxicol; 2011 Mar; 108(3):163-70. PubMed ID: 20977679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection.
    Custodio JM; Yin X; Hepner M; Ling KH; Cheng A; Kearney BP; Ramanathan S
    J Clin Pharmacol; 2014 Apr; 54(4):378-85. PubMed ID: 24142299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.
    Kakuda TN; Schöller-Gyüre M; Workman C; Arasteh K; Pozniak AL; De Smedt G; Beets G; Peeters M; Vandermeulen K; Woodfall BJ; Hoetelmans RM
    Antivir Ther; 2008; 13(5):655-61. PubMed ID: 18771049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
    Vourvahis M; Davis J; Langdon G; Layton G; Fang J; Choo HW; Hansson AG; Tawadrous M
    Antivir Ther; 2013; 18(6):745-54. PubMed ID: 23558061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
    Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of different meal compositions and fasted state on the oral bioavailability of etravirine.
    Schöller-Gyüre M; Boffito M; Pozniak AL; Leemans R; Kakuda TN; Woodfall B; Vyncke V; Peeters M; Vandermeulen K; Hoetelmans RM
    Pharmacotherapy; 2008 Oct; 28(10):1215-22. PubMed ID: 18823217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.
    Taburet AM; Piketty C; Chazallon C; Vincent I; Gérard L; Calvez V; Clavel F; Aboulker JP; Girard PM
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2091-6. PubMed ID: 15155205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers.
    Peeters M; Janssen K; Kakuda TN; Schöller-Gyüre M; Lachaert R; Hoetelmans RM; Woodfall B; De Smedt G
    Ann Pharmacother; 2008 Jun; 42(6):757-65. PubMed ID: 18445705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers.
    Droste JA; Verweij-van Wissen CP; Kearney BP; Buffels R; Vanhorssen PJ; Hekster YA; Burger DM
    Antimicrob Agents Chemother; 2005 Feb; 49(2):680-4. PubMed ID: 15673751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and food interaction of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy volunteers.
    Lu C; Jia Y; Chen L; Ding Y; Yang J; Chen M; Song Y; Sun X; Wen A
    J Clin Pharm Ther; 2013 Apr; 38(2):136-40. PubMed ID: 23278367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
    Schöller-Gyüre M; Kakuda TN; De Smedt G; Woodfall B; Berckmans C; Peeters M; Hoetelmans RM
    Clin Ther; 2010 Feb; 32(2):328-37. PubMed ID: 20206790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.
    Kearney BP; Mathias A
    Pharmacotherapy; 2009 Aug; 29(8):924-9. PubMed ID: 19637945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steady-state pharmacokinetics of etravirine and lopinavir/ritonavir melt extrusion formulation, alone and in combination, in healthy HIV-negative volunteers.
    Schöller-Gyüre M; Kakuda TN; Witek J; Akuma SH; De Smedt G; Spittaels K; Vyncke V; Hoetelmans RM
    J Clin Pharmacol; 2013 Feb; 53(2):202-10. PubMed ID: 23436265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.